Requiring rigorous trials with proper controls strengthens vaccine trust and regulatory integrity. The FDA should demand higher standards for approval, especially for drugs treating common conditions. Forcing industry to fund more robust studies improves the entire system.
Moderna invested $750 million in trials proving mRNA-1010 beats traditional vaccines by 25% for vulnerable seniors, yet the FDA invented impossible demands that crashed stocks 18% and halted 150 million lifesaving doses. This political sabotage forces reliance on slower, weaker egg-based shots while punishing innovation.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.4.1